D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM)
L. Garland,Cathryn Rankin,Katherine Scott,R. Nagle,M. Lobell,David R. Gandara,Saul E. Rivkin,Wolfram E. Samlowski,James N. Atkins,Ernest C. Borden +9 more
TL;DR: Lack of phosphorylation of AKT and lack of PTEN expression in the AKT pathway downstream of EGFR may be a mechanism of MPM's clinical resistance to OSI-774, suggesting that the ERK signaling pathway is important in the molecular pathogenesis of the more aggressive sarcomatous phenotype ofMPM.
Journal ArticleDOI
Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study
Cheryl Ho,Randeep Sangha,Laurel A. Beckett,Michael Tanaka,Derick H Lau,Daniel B. Eisen,Rachel A. Burich,Paul A. Luciw,Imran Khan,Philip C. Mack,David R. Gandara,Angela M. Davies +11 more
TL;DR: The safety and feasibility of escalating weekly doses of cetuximab are examined, testing the hypothesis of the relationship of dose-dependent skin toxicity and efficacy, and there was no direct correlation of the grade of rash with dose in this group of patients with heterogenous solid tumors.
Journal ArticleDOI
Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.
Yingwei Qi,Katie L. Allen Ziegler,Shauna L. Hillman,Mary W. Redman,Steven E. Schild,David R. Gandara,Alex A. Adjei,Sumithra J. Mandrekar +7 more
TL;DR: The authors evaluated the impact of the progression date (PD) determination approach on PFS estimates and found that it had an uncertain impact on overall survival estimates.
Journal ArticleDOI
Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
TL;DR: The potential roles for IGF-1R and HDAC inhibitors in NSCLC management, and the need for optimizing treatment by seeking a more personalized approach to care are discussed.
Journal ArticleDOI
O-89 S0003: Paclitaxel/carboplatin (PC) versus PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III southwest oncology group (SWOG) trial
Stephen K. Williamson,John Crowley,Primo N. Lara,Robert W. Tucker,Jason McCoy,Derick H Lau,David R. Gandara +6 more